cell:美国科学家成功确认6种寨卡病毒抗体

ipsvirus

国际知名杂志《Cell》于2016年7月27日刊文称，研究人员已经成功确认了6种或能预防寨卡病毒感染的抗体。

美国华盛顿大学医学院的研究小组完成了相关实验。专家称，抗体的确认是进行疫苗研发的“重要一步”。这6种抗体都经过试验证实具有抗寨卡病毒的效果，有望使用在寨卡热诊断等不同领域。

论文作者帝布德·弗李蒙多（Daved Fremont）教授表示，本次确认的这6种抗体分别与非洲、亚洲、美洲系统的寨卡病毒株具有相同程度的作用效果。

寨卡病毒可致新生儿小头畸形，主要在巴西、委内瑞拉等中、南美洲国家流行。本次的研究成果将会成为开发孕妇用疫苗的关键。妊娠期女性的免疫系统比较脆弱，因此即使只是少量的病毒也可能带来严重影响，普通人使用的疫苗大多以病原体为原料进行制作，并不适合孕妇使用。

来源：科技世界网

ipsvirus

Structural Basis of Zika Virus-Specific Antibody Protection

Haiyan Zhao7, Estefania Fernandez7, Kimberly A. Dowd, Scott D. Speer, Derek J. Platt, Matthew J. Gorman, Jennifer Govero, Christopher A. Nelson, Theodore C. Pierson, Michael S. Diamond, Daved H. Fremont

Highlights
•New ZIKV-specific monoclonal antibodies are identified
•Three distinct epitopes on E protein DIII are defined by X-ray crystallography
•DIII lateral ridge antibodies broadly neutralize ZIKV infection and protect in mice

Summary
Zika virus (ZIKV) infection during pregnancy has emerged as a global public health problem because of its ability to cause severe congenital disease. Here, we developed six mouse monoclonal antibodies (mAbs) against ZIKV including four (ZV-48, ZV-54, ZV-64, and ZV-67) that were ZIKV specific and neutralized infection of African, Asian, and American strains to varying degrees. X-ray crystallographic and competition binding analyses of Fab fragments and scFvs defined three spatially distinct epitopes in DIII of the envelope protein corresponding to the lateral ridge (ZV-54 and ZV-67), C-C’ loop (ZV-48 and ZV-64), and ABDE sheet (ZV-2) regions. In vivo passive transfer studies revealed protective activity of DIII-lateral ridge specific neutralizing mAbs in a mouse model of ZIKV infection. Our results suggest that DIII is targeted by multiple type-specific antibodies with distinct neutralizing activity, which provides a path for developing prophylactic antibodies for use in pregnancy or designing epitope-specific vaccines against ZIKV.

http://www.cell.com/cell/abstract/S0092-8674(16)30927-8

DavidCui

尽快有公司将其进行ELISA试剂盒生产并应用。

douban

DavidCui 发表于 2016-9-24 16:54
尽快有公司将其进行ELISA试剂盒生产并应用。

抗原试剂盒要考虑到与登革及乙脑病毒的交叉